---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-092219"
form_type: "8-K"
ticker: "HYPD"
cik: "0001682639"
company_name: "HYPERION DEFI, INC."
filed_at: "2023-08-16T23:59:59+00:00"
generated_at: "2026-06-11T08:37:15.725950+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eyenovia acquires exclusive U.S. rights to Formosa's APP13007 (clobetasol) for ocular surgery inflammation/pain

## Summary
- PDUFA action date for APP13007 (clobetasol) set for March 4, 2024.
- Upfront payment of single-digit million in cash and stock; up to $4M in development and $80M in sales milestones.
- APP13007 offers 2x/day dosing vs. standard 4x/day for post-surgical ocular inflammation/pain.
- Eyenovia plans to develop clobetasol-Optejet for dry eye, a $3.6B U.S. market.
- Product complements existing Mydcombi sales force; addresses >7M annual ocular surgeries.

## SEC filing metadata
- accession: 0001104659-23-092219
- form_type: 8-K
- ticker: HYPD
- cik: 0001682639
- company_name: HYPERION DEFI, INC.
- filed_at: 2023-08-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682639/000110465923092219/0001104659-23-092219-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682639/000110465923092219/tm2323901d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-092219
- JSON: https://secwatch.observer/filing/0001104659-23-092219.json
- Plain text: https://secwatch.observer/filing/0001104659-23-092219.txt

## Key facts
- Material Agreements
  HYPERION DEFI, INC. entered into License Agreement with Formosa Pharmaceuticals, Inc. valued at $2 million within 45 days of the effective date of the agreement (effective 2023-08-15).
  - Action: entry
  - Agreement: license
  - Counterparty: Formosa Pharmaceuticals, Inc.
  - Value: $2 million within 45 days of the effective date of the agreement
  - Effective: 2023-08-15
  source text: On August 15, 2023, Eyenovia, Inc. (the “Company”), entered into a license agreement (the “License Agreement”) with Formosa Pharmaceuticals, Inc. (“Formosa”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682639/000110465923092219/0001104659-23-092219-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.